Literature DB >> 15781320

Membrane type-matrix metalloproteinases and tumor progression.

N E Sounni1, A Noel.   

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases that process growth factors, growth factor binding proteins, cell surface proteins, degrade extracellular matrix (ECM) components and thereby play a central role in tissue remodeling and tumor progression. Membrane-type matrix metalloproteinases (MT-MMPs) are a recently discovered subgroup of intrinsic plasma membrane proteins. Their functions have been extended from pericellular proteolysis and control of cell migration to cell signaling, control of cell proliferation and regulation of multiple stages of tumor progression including growth and angiogenesis. This review sheds light on the new functions of MT-MMPs and their inhibitors in tumor development and angiogenesis, and presents recent investigations that document their influence on various cell functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781320     DOI: 10.1016/j.biochi.2004.07.012

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  47 in total

1.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

2.  IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells.

Authors:  Ching-Yi Cheng; Chang-Ting Kuo; Chih-Chung Lin; Hsi-Lung Hsieh; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Acid treatment of melanoma cells selects for invasive phenotypes.

Authors:  Raymond E Moellering; Kvar C Black; Chetan Krishnamurty; Brenda K Baggett; Phillip Stafford; Matthew Rain; Robert A Gatenby; Robert J Gillies
Journal:  Clin Exp Metastasis       Date:  2008-02-27       Impact factor: 5.150

4.  Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3 and suppression of AP-1.

Authors:  Hao H Ho; Taras T Antoniv; Jong-Dae Ji; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Immunohistochemical detection of MMP-2 and MMP-9 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Toshikazu Kondo
Journal:  Int J Legal Med       Date:  2010-07-10       Impact factor: 2.686

Review 6.  Epithelial-to-mesenchymal transitions and circulating tumor cells.

Authors:  Arnaud Bonnomet; Anne Brysse; Anthony Tachsidis; Mark Waltham; Erik W Thompson; Myriam Polette; Christine Gilles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-07       Impact factor: 2.673

Review 7.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

Review 8.  Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development.

Authors:  Lidiya S Orlichenko; Derek C Radisky
Journal:  Clin Exp Metastasis       Date:  2008-02-20       Impact factor: 5.150

9.  Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.

Authors:  D Pastuszak-Lewandoska; J Kordiak; K H Czarnecka; M Migdalska-Sęk; E Nawrot; D Domańska-Senderowska; J M Kiszałkiewicz; A Antczak; P Górski; E Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

10.  Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo.

Authors:  Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2014-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.